Targeted radiation therapy for relapsed neuroblastoma
Part of Cancer clinical trials.
This trial tests a new type of targeted radiation treatment for children and adults with neuroblastoma that has come back or not responded to other treatments. The radiation is attached to a substance that seeks out neuroblastoma cells, aiming to destroy them while limiting harm to healthy tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have neuroblastoma that can be seen on a special scan called MIBG (a scan that shows where the tumor is).
- You must be at least 1 year old.
- You need to be feeling well enough to do daily activities (score of 50% or higher on a standard scale).
- Your organs (like kidneys, liver, and bone marrow) must be working well enough.
- You cannot have had certain cancer treatments (like specific antibodies, radiation therapy, or stem cell transplants) recently, and you must not have serious infections or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two special types of imaging scans that look for neuroblastoma tumors. The imaging uses safe radioactive tracers to help doctors better see the cancer and plan treatment.
This trial tests a combination of four drugs (chidamide, dinutuximab beta, irinotecan, and temozolomide) for children whose neuroblastoma has returned or isn't responding to standard treatment. It aims to see if this mix can shrink the tumor or stop it from growing.
This early-phase trial tests a new drug called IR-101 for children with high-risk neuroblastoma that has come back or isn't responding to treatment. It aims to see if the drug is safe and can help shrink tumors that show up on a MIBG scan.
This trial uses a radioactive medicine called MIBG to target and kill neuroblastoma or related tumor cells that have not responded to standard treatments. It may help patients whose cancer has come back or is hard to treat.
This trial gives a radioactive drug called 131-I-MIBG to treat neuroblastoma that has not gone away or has come back. The drug targets cancer cells, and stem cells are given back after treatment to help the body recover.
This trial tests a combination of targeted radiation (MIBG) with two medicines, vorinostat and dinutuximab, for children and young adults with high-risk neuroblastoma that has returned or not fully responded to earlier treatment. The goal is to see if adding these medicines helps the radiation work better and improves outcomes.
Hear when a new Neuroblastoma (NB) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.